NCT05245292View on ClinicalTrials.gov

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

3BNC117-LS

Intravenous infusion of 3BNC117-LS at 30 mg/kg

DRUG

10-1074-LS

Intravenous infusion of 10-1074-LS at 10 mg/kg

DRUG

N803

Subcutaneous injections of N803 at 6 mcg/kg

Trial Locations (3)

10021

Weill Cornell Medicine, Cornell Clinical Trials Unit, New York

10065

The Rockefeller University, New York

19104

Perelman School of Medicine University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

University of Pennsylvania

OTHER

lead

Rockefeller University

OTHER